key: cord-0776355-et7mp4qo
authors: Luca, Giuseppe De; Nardin, Matteo; Algowhary, Magdy; Uguz, Berat; Oliveira, Dinaldo C; Ganyukov, Vladimir; Zimbakov, Zan; Cercek, Miha; Okkels, Lisette; LOH, Poay Huan; Calmac, Lucian; i Ferrer, Gerard Roura; Quadros, Alexandre; Milewski, Marek; D'Uccio, Fortunato Scotto; von Birgelen, Clemens; Versaci, Francesco; Berg, Jurrien Ten; Casella, Gianni; Lung, Aaron Wong Sung; Kala, Petr; Gil, José Luis Díez; Carrillo, Xavier; Dirksen, Maurits; Becerra-Munoz, Victor M.; Kang-yin Lee, Michael; Juzar, Dafsah Arifa; Joaquim, Rodrigo de Moura; Paladino, Roberto; Milicic, Davor; Davlouros, Periklis; Bakraceski, Nikola; Zilio, Filippo; Donazzan, Luca; Kraaijeveld, Adriaan; Galasso, Gennaro; Arpad, Lux; Lucia, Marinucci; Vincenzo, Guiducci; Menichelli, Maurizio; Scoccia, Alessandra; Yamac, Aylin Hatice; Mert, Kadir Ugur; Rios, Xacobe Flores; Kovarnik, Tomas; Kidawa, Michal; Moreu, Josè; Flavien, Vincent; Fabris, Enrico; Martínez-Luengas, Iñigo Lozano; Boccalatte, Marco; Ojeda, Francisco Bosa; Arellano-Serrano, Carlos; Caiazzo, Gianluca; Cirrincione, Giuseppe; Kao, Hsien-Li; Forés, Juan Sanchis; Vignali, Luigi; Pereira, Helder; Manzo, Stephane; Ordoñez, Santiago; Özkan, Alev Arat; Scheller, Bruno; Lehtola, Heidi; Teles, Rui; Mantis, Christos; Antti, Ylitalo; Silveira, João António Brum; Zoni, Rodrigo; Bessonov, Ivan; Savonitto, Stefano; Kochiadakis, George; Alexopulos, Dimitrios; Uribe, Carlos E; Kanakakis, John; Faurie, Benjamin; Gabrielli, Gabriele; Barrios, Alejandro Gutierrez; Bachini, Juan Pablo; Rocha, Alex; Tam,; Rodriguez, Alfredo; Lukito, Antonia Anna; Saint-Joy, Veauthyelau; Tuccillo, Gustavo Pessah Andrea; Cortese, Giuliana; Parodi, Guido; Burgadha, Mohammed Abed; Kedhi, Elvin; Lamelas, Pablo; Suryapranata, Harry; Verdoia, Monica
title: Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic
date: 2021-10-30
journal: Diabetes epidemiology and management
DOI: 10.1016/j.deman.2021.100022
sha: 64d484c6396b9970235501389f40db286c954f47
doc_id: 776355
cord_uid: et7mp4qo

Background During the coronavirus disease 2019 (COVID-19) pandemic, concerns have been arisen on the use of renin-angiotensin system inhibitors (RASI) due to the potentially increased expression of Angiotensin-converting-enzyme (ACE)2 and patient's susceptibility to SARS-CoV2 infection. Diabetes mellitus have been recognized favoring the coronavirus infection with consequent increase mortality in COVID-19. No data have been so far reported in diabetic patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population deserving of RASI treatment. Methods The ISACS-STEMI COVID-19 registry retrospectively assessed STEMI patients treated with primary percutaneous coronary intervention (PPCI) in March/June 2019 and 2020 in 109 European high-volume primary PCI centers. This subanalysis assessed the prognostic impact of chronic RASI therapy at admission on mortality and SARS-CoV-2 infection among diabetic patients. Results Our population is represented by 3,812 diabetic STEMI patients undergoing mechanical reperfusion, 2,038 in 2019 and 1,774 in 2020. Among 3,761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARSCoV2 infection (1.6% vs 1.3%, respectively, p=0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower in-hospital mortality (3.3% vs 15.8%, p < 0.0001), consistently both in 2019 and in 2010. . Conclusions This is first study to investigate the impact of RASI therapy on prognosis and SARSCoV2 infection of diabetic patients experiencing STEMI and undergoing PPCI during the COVID-19 pandemic. Both pre-admission chronic RASI therapy and in-hospital RASI did not negatively affected patients’ survival during the hospitalization, neither increased the risk of SARS-CoV2 infection. Trial registration number NCT 04412655

Results. Our population is represented by 3,812 diabetic STEMI patients undergoing mechanical reperfusion, 2,038 in 2019 and 1,774 in 2020. Among 3,761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARSCoV2 infection (1.6% vs 1.3%, respectively, p=0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower inhospital mortality (3.3% vs 15.8%, p < 0.0001), consistently both in 2019 and in 2010. .

SARSCoV2 infection of diabetic patients experiencing STEMI and undergoing PPCI during the COVID-19 pandemic. Both pre-admission chronic RASI therapy and in-hospital RASI 5 did not negatively affected patients' survival during the hospitalization, neither increased the risk of SARS-CoV2 infection.

The global pandemic of coronavirus disease 2019 (COVID-19) has dramatically impacted on healthcare system worldwide, and its effects are still ongoing. As of 30th June 2021, more than 185 million cases of COVID-19 have been reported in more than 185 countries and territories, resulting in near 4 million deaths, especially in Europe, the United States, India and Latin America 1 .

Increasing interests have been focused on a potential harmful role of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), jointly named reninangiotensin system inhibitors (RASI). These drugs were assumed playing a role in the SARS-CoV2 infect action, favoring the virus cell entry through upregulation of angiotensin-converting enzyme 2 (ACE2). [2] [3] [4] The enhanced expression of ACE2 during RASI treatment, which was suspected to increase the patient's susceptibility to COVID-19, have pulled up several concerns, especially in high risk population as diabetics, that consistently benefit from RASI treatment, especially in light of their high cardiovascular risk profile that significantly impact on long-term survival. 5, 6 As stated by international societies guidelines, 7 RASI are strongly suggested as first line treatment for hypertension in patients with diabetes mellitus particularly in those with evidence of end-organ damage, like albuminuria and left ventricular hypertrophy [7] [8] [9] . Considering the high prevalence of hypertension among diabetics, >60% 10 , a specific attention has been reserved to these patients, already showing independently enhanced risk of COVID-19 adverse consequences, that could get even worse. 11 6 Not univocal messages were provided by international professional societies, especially in the first months of the pandemic, regarding recommendation for patients under treatment with a RASI, even if the general agreement was to continue the ongoing therapy until final evidences from sufficiently powered studies. [12] [13] [14] No specific increased risks of COVID-19 or related adverse events for RASI were detected in general population. [15] [16] [17] [18] However, no definite data have been so far reported in diabetics patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population with extensive use of RASI.

Infarction (ISACS-STEMI) COVID-19 was established in response to the emerging outbreak of COVID-19 to provide a worldwide snapshot and estimates of the true impact of the COVID-19 pandemic on the treatment and outcome of STEMI patients treated by PPCI. 19, 20 The aim of the present investigation was to inquire whether chronic use of RASI at the time of admission and their use during the hospitalization impacted on susceptibility to COVID-19 and on mortality risk among diabetic patients with STEMI undergoing primary angioplasty.

Our study population is represented by patients enrolled in the ISACS-STEMI COVID-19 (NCT 04412655), a retrospective multicenter registry including STEMI patients enrolled by 109 high-volume primary percutaneous coronary intervention (PCI) centers from Europe, Latin America, South-East Asia and North-Africa. This study was conducted to compare STEMI patients treated from March 1 st until June 30 th of 2019 with those admitted within the same period of 2020.

We collected demographic, clinical, procedural data, data on total ischemia time, door-toballoon time, referral to primary PCI facility, PCI procedural data, in hospital mortality. The study was approved by the Ethical Committee of AOU Maggiore della Carità. Novara.

Detailed data have previously been provided. 19, 20 Statistics Data analysis was performed by using SPSS Statistics Software 23.0 (IBM SPSS Inc., Chicago, Illinois). Quantitative variables were described using median and interquartile range.

Absolute frequencies and percentages were used for qualitative variables. ANOVA or Mann-Whitney and chi-square test were used for continuous and categorical variables, respectively. Normal distribution of continuous variables was tested by the Kolmogorov-Smirnov test.

A propensity score analysis was performed in order to overcome the potential bias related to differences in baseline characteristics. For each patient, a propensity score indicating the likelihood of having chronic RASI or in-Hospital RASI administration was calculated by use of forward logistic regression analysis that identified variables independently associated with RASI prescription.

The discriminatory capacity of the propensity score was assessed by the area under the ROC curve (c-statistic) as an index of model performance. On the basis of the propensity score, the population was divided in four groups (from the lowest to the highest probability to have RASI prescribed) by the use of quartiles. The impact of RASI on mortality and SARS-2 positivity was evaluated for each quartile, separately. Furthermore, multivariable logistic regression analyses were performed to identify the association of RASI with in-hospital mortality and SARS-CoV-2 infection after adjustment for baseline confounding factors between the two groups, including the propensity score. All significant variable (set at a P-value <0.1) were entered in block into the model.

A p < 0.05 was considered statistically significant. The data coordinating center was established at the Eastern Piedmont University, Novara, Italy.

Of the 16,077 STEMI patients undergoing mechanical reperfusion included in the study, 3,812 (23.7%) were diabetic, in whom complete demographic, clinical, procedural, and outcome data were available as well as information regarding in hospital RASI therapy. Patients with informative data on RASI treatment at admission were 3,761 (98.7%). Higher RASI discontinuation rate after hospital admission was observed was observed in 2019 compared to 2020 (46.2% in 2019 vs 39.0 % in 2020, p=0.001). Table 1 shows baseline characteristics of patients in overall cohort and with versus without chronic RASI therapy at admission, according to the year of treatment. Almost all differences detected were consistent both in 2019 and 2020 cohort. In particular, patients on RASI were older, more often female, with higher burden of comorbidities including hypertension, hypercholesterolemia, and had already experienced a STEMI, and coronary revascularization, but displayed lower prevalence of active smoking. Patients on RASI had a lower total ischemia time and less often underwent rescue PCI.

With regards to treatment during the hospitalization, patients treated with RASI were younger, more often male, suffering of hypercholesterolemia, previous STEMI, coronary revascularization. Patients experienced out-of-hospital cardiac arrest and cardiogenic shock were less frequent under in-hospital RASI therapy (Table 2) .

Angiographic and procedural characteristics are shown in Table 1S for patients under RASI at admission, while in Table 2S are reported data for patients treated with RASI in hospital.

Radial access was performed less frequently in patients with RASI treatment ad admission in the overall cohort and in 2019, while no differences were observed for the same period of 2020. Higher prevalence of in-stent thrombosis was found in patients under RASI, consistently in both 2019 and 2020. Conversely, patients undergoing thrombectomy and DES implantation were more likely treated with RASI during the hospitalization.

Chronic RASI treatment at hospital admission was overall related to lower in-hospital mortality and 30-day mortality (Figure 1) . Results were confirmed in 2019 but in 2020 did not reach the statistical significance (p=0.296). The benefits were confirmed in almost all the quartiles of the propensity score ( Figure 1S In-hospital treatment with RASI showed significant benefits in in-hospital and 30-day mortality that was consistent in both 2019 and 2020 (Figure 2) . The benefits were confirmed in almost all the quartiles of the propensity score ( Figure 2S Both chronic treatment and in hospital therapy with RASI did not affect the SARS-CoV2 positivity (n = 26) (Figure 3 ).

The main finding of the present study is that among diabetic patients experiencing STEMI and treated with mechanical reperfusion during the COVID-19 pandemic, chronic RASI therapy at admission showed a lower rate of death not raising the statistical significance in 2020, whereas In-hospital treatment with RASI resulted in a significantly lower mortality in both pandemic and prepandemic period. Both chronic treatment and in hospital therapy with RASI did not affect the SARS-CoV2 positivity.

Diabetes mellitus is a condition enhancing patients' cardiovascular risk profile due to damages on both microvascular and macrovascular sides [21] [22] [23] . Prolonged glucose homeostasis impairment leads to endothelial dysfunction, atherosclerosis progression and pro-thrombotic environmental, recognizing diabetics as patients at higher risk for cardiovascular events. RASI constitute a cornerstone of treatment in various cardiovascular diseases providing robust evidences in reducing death and morbidity [24] [25] [26] [27] . Their benefits were confirmed also among diabetics, indeed RASI are considered first treatment option in several condition, including hypertension. 28 However, previous animal studies have reported worries on RAS modulation, suggesting that ACE2 expression might play a negative prognostic role in COVID-19 patients: the ACE2 enzyme is a cell membrane protein, that is used by the SARS-CoV2 virus to enter cells 2, 29 . Given that experimental studies showed that angiotensin receptor blockers (ARBs) and an ACE inhibitors (ACEIs) could increase ACE2 expression in cardiovascular and renal systems 30, 31 , favouring the conversion of angiotensin II to angiotensin (1-7) 32 , concerns have been raised on potential detrimental consequences driven by ARBs and ACEIs treatment on SARS-CoV2 infection and the severity of the COVID-19. 33 Clinical evidences on the of ACEI/ARBs in patients with COVID-19 has been controversial in part due to early reports from China, showing higher mortality in hypertensive patients admitted for COVID-19. [34] [35] [36] [37] [38] Those analysis were hampered by small cohort and main confounding factors such as older age and cardiovascular disease, were collinear with hypertension. Further and larger studies have found no harmful effects or even beneficial effects from RASI therapy [15] [16] [17] [18] . In a large population-based case-control study in the Lombardy region of Italy performed by Mancia et al 14 , a total of 6,272 case patients with confirmed SARS-CoV2 infection were matched with more than 30,000 patients according to age, sex and municipality of residence. RASI were detected more frequently used in COVID-19 patients compared to controls, but no significant increased risk of SARS-CoV2 infection was found for chronic RASI treatment.

Diabetes mellitus confers per se a higher risk of mortality and adverse events in patients with cardiovascular disease 28 . Also in COVID-19 an increased death rate was independently associated with diabetes mellitus and metabolic diseases 39-41 : a retrospective analysis from Bode et al including 1,122 patients showed a 4-fold increased mortality among diabetics compared to non-diabetics, with a further enhanced risk of death in case of uncontrolled hyperglycemia. 42 Main mechanisms, which diabetes mellitus and high glucose promote SARS-CoV2 replication through, are strictly related to enhanced production of reactive oxygen species and pro-inflammatory cytokines. 43 Similarly, are the findings from Zhu et al that showed significant clinical benefits correlated with improved glycemic control during COVID-19 hospitalization.

Therefore, inquiring the interplay between renin-angiotensin system and diabetes mellitus during COVID-19 results essential to evaluate patients' prognosis. In fact, the diabetic status favors SARS-CoV2 infection and could be influenced by RASI therapy. 44 The relationship between increased ACE2 expression during RASI treatment and pro-inflammatory environment in diabetics is not completely established, with few studies that addressed their resulting balance. Aghaaliakbari et al retrospectively investigated the effect of ACEi and diabetes in COVID-19 patients: among 153 diabetics, ACEi treatment was found significantly increasing the risk of mortality. 45 Conversely, Ramos-Rincón et al reported in diabetics with more than 80 years old a potential protective role of chronic treatment with ARB. 46 In a randomized trial testing the continuation versus discontinuation of RASI, authors showed that they can be safely continued in patients admitted for COVID-19, consistently in diabetic and non-diabetics. 47 However, so far no data have been reported in diabetic patients with STEMI, representing a population with a very high adverse event risk and (guideline-recommended) RASI use in the majority of patients. 48 Our report is the first study focused on STEMI patients with diabetes undergoing mechanical reperfusion, including more than 3,800 diabetics undergoing mechanical reperfusion. We found that chronic RASI at admission did not affect the prevalence of SARS-CoV2 infection and showed a lower rate of death not raising the statistical significance in 2020. Furthermore, in-hospital RASI treatment was associated with a significantly lower mortality, consistently in 2019 and 2020, without affecting the prevalence of SARSCoV2 infection. Therefore, confirming our previous report in a general population, 49 13 the present study confirms the overall mortality benefits of RASI among diabetic patients with STEMI. Moreover, it does not suggest a link between RASI therapy and COVID-19 susceptibility or subsequent worse outcomes among these patients.

Professional societies have issued position statements that ACEI/ARBs should not be discontinued that this study supports. 50 Support of continuing RASI therapy was yielded by the recent randomized BRACE-CORONA Trial, 659 patients with chronic RASI therapy at admission and confirmed diagnosis of COVID-19 were randomly assigned to a temporary 30-day suspension or continuation of RASI therapy. No differences were observed for 30day mortality (2.8% vs 2.7%) between the two groups. 51 Further randomized trials focused on diabetic patients are needed to clarify the protective or harmful effects of RASI treatment during COVID-19. Benefits provided by RASI seems confirmed in diabetics experiencing STEMI treated with mechanical reperfusion, without increasing the risk for COVID-19 and in-hospital mortality.

This study is limited by its retrospective, non-randomized design. As may be expected, diabetics on RASI therapy differed from the other patients in comorbidities, firstly hypertension prevalence, however the results on mortality were not affected by baseline differences.

Moreover, our research was conducted during a pandemic emergency, which was a challenge and expected to encounter some missing data. Nevertheless, considering all adversities, the proportion of patients with missing data regarding in-hospital RASI therapy was tolerable.

The choice of interrupt RASI treatment ad admission as well as its introduction during the hospitalization was made by physicians and at their own discretion: that, together with the uncertainty of RASI harm on SARS-CoV2 infection risk, could have impacted patients' outcome, even if no increased mortality was found in analyses of both chronic and in hospital treatments.

As we did not collect information on the type and dosage of RASI, we cannot perform a further in-depth assessment of prognostic implications. Finally, although our database comprised almost 3,800 diabetic STEMI patients with known in-hospital pharmacological therapy, procedural features and clinical outcome following mechanical reperfusion procedure, the evaluation of the prognostic impact of RASI treatment among SARS-CoV2-positive patients was limited due to the low prevalence of the infection.

This is the first study investigating the prognostic impact of RASI therapy in patients with diabetes mellitus experiencing STEMI treated with mechanical reperfusion during COVID-19 pandemic. Our main finding is that RASI therapy was associated with an overall significant reduction in mortality, without any negative effect on SARS-CoV2 infection. Therefore, waiting for future dedicated and randomized trials, during the pandemic RASI should not be suspended or omitted among these high-risk patients suffering from STEMI and undergoing mechanical reperfusion.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus

Impact of diabetes on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: insights from the ELDERLY ACS 2 trial

ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial h

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions

Cardiovascular risk factors and mortality in 17 hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients

The New England journal of medicine

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. The New England journal of medicine

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. The New England journal of medicine

aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry

Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI

Excess Mortality among Persons with Type 2 Diabetes. The New England journal of medicine

Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks

European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati

Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

Angiotensinconverting-enzyme inhibition in stable coronary artery disease. The New England journal of medicine

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme

Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic

Preventing a covid-19 pandemic

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet. Respiratory medicine

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Case-Fatality Rate and Characteristics of Patients 22

Dying in Relation to COVID-19 in Italy

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. The European respiratory journal

Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory medicine

Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system

Cardiometabolic therapy and mortality in very old patients with diabetes hospitalized due to COVID-19. The journals of gerontology. Series A, Biological sciences and medical sciences

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. The Lancet. Respiratory medicine

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion

Joint HFSA/ACC/AHA Statement Addresses 24

Concerns Re: Using RAAS Antagonists in COVID-19

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19

STEMI = ST-segment Elevation Myocardial Infarction